BII
URGN icon

Bainco International Investors’s UroGen Pharma URGN Stock Holding History

Bainco International Investors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-72,461
Closed -$2.28M – 95
2017
Q3 		$2.28M Buy
+72,461
New +$1.6M 0.27% 62

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DP
DSAM Partners London, United Kingdom $176M AUM 83.78% 1-Year Est. Return

Bainco International Investors's URGN Position: Q4 2017 in Review

Bainco International Investors sold out of UroGen Pharma (URGN) in Q4 2017, closing a stake of 72,461 shares — an estimated $2.28M sold.

Bainco International Investors first reported a position in URGN in Q3 2017 and held it in 1 quarter. The position peaked at $2.28M in Q3 2017. 41 funds tracked by Wall St. Rank hold URGN as of Q4 2017.

  • Bainco International Investors reported no remaining UroGen Pharma position as of Q4 2017 after selling out during the quarter.
  • Bainco International Investors sold 72,461 UroGen Pharma shares in Q4 2017, an estimated $2.28M.
  • Bainco International Investors first reported a position in UroGen Pharma in Q3 2017 and held it in 1 quarter.
  • Bainco International Investors's UroGen Pharma position peaked at $2.28M in Q3 2017.
  • 41 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2017.

Based on Bainco International Investors's 13F filing for Q4 2017, filed 14 Feb 2018.